Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Consensus "Moderate Buy": Nine analysts give Xencor a consensus rating of Moderate Buy with an average 12‑month price target of about $24.38, though individual views vary widely (Barclays $27 overweight vs. JPMorgan $13 neutral and some sell ratings).
• Mixed ownership activity: company insiders have sold a total of 44,020 shares (~$499,817) over the last 90 days (insiders own 5.23%), while major institutions — including Primecap, Vanguard, BVF, RTW and State Street — have recently increased stakes, with BVF adding sharply (+160.3%).
• Recent financials show a mixed operational picture: Xencor beat EPS expectations this quarter (‑$0.09 vs. est. ‑$0.64) but revenue fell 46.6% year‑over‑year and the company remains unprofitable (negative margins), with a market cap of about $891M and a 12‑month stock range of $6.92–$18.69.

Shares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $24.3750.

Several equities analysts have recently commented on the company. Barclays raised their price target on Xencor from $26.00 to $27.00 and gave the company an "overweight" rating in a research note on Thursday, February 26th. Weiss Ratings reissued a "sell (d-)" rating on shares of Xencor in a report on Friday, March 27th. Wall Street Zen raised shares of Xencor from a "sell" rating to a "hold" rating in a report on Saturday, April 18th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating and set a $13.00 price objective (down from $18.00) on shares of Xencor in a report on Tuesday, March 24th.

Insider Activity at Xencor

In related news, VP John R. Desjarlais sold 4,118 shares of Xencor stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $11.25, for a total transaction of $46,327.50. Following the transaction, the vice president directly owned 266,333 shares of the company's stock, valued at $2,996,246.25. This trade represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Celia Eckert sold 3,244 shares of Xencor stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $11.25, for a total value of $36,495.00. Following the completion of the transaction, the senior vice president owned 78,685 shares in the company, valued at $885,206.25. This trade represents a 3.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 44,020 shares of company stock valued at $499,817 over the last ninety days. 5.23% of the stock is owned by company insiders.

Hedge Funds Weigh In On Xencor

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Primecap Management Co. CA grew its stake in Xencor by 1.4% in the third quarter. Primecap Management Co. CA now owns 10,675,022 shares of the biopharmaceutical company's stock valued at $125,218,000 after purchasing an additional 147,700 shares during the last quarter. Vanguard Group Inc. grew its stake in Xencor by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company's stock valued at $109,703,000 after purchasing an additional 61,692 shares during the last quarter. BVF Inc. IL grew its stake in Xencor by 160.3% in the fourth quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company's stock valued at $109,217,000 after purchasing an additional 4,393,579 shares during the last quarter. RTW Investments LP grew its stake in Xencor by 8.9% in the fourth quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company's stock valued at $103,763,000 after purchasing an additional 556,407 shares during the last quarter. Finally, State Street Corp grew its holdings in Xencor by 22.7% in the fourth quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company's stock worth $69,006,000 after purchasing an additional 833,423 shares during the last quarter.

Xencor Stock Performance

Shares of Xencor stock opened at $12.15 on Wednesday. The firm has a market cap of $891.08 million, a P/E ratio of -9.80 and a beta of 0.99. The company has a current ratio of 6.25, a quick ratio of 6.25 and a debt-to-equity ratio of 0.12. Xencor has a 12 month low of $6.92 and a 12 month high of $18.69. The stock's fifty day moving average price is $12.20 and its 200-day moving average price is $13.66.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.55. The firm had revenue of $28.24 million for the quarter, compared to analyst estimates of $29.97 million. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The business's revenue for the quarter was down 46.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.62) earnings per share. On average, equities research analysts expect that Xencor will post -2.87 earnings per share for the current fiscal year.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.